Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only manageable grade 1 to 2 toxicities and no cardiovascular or bleeding ...

Overview of Platelet Aggregation Devices MarketThe global Platelet Aggregation Devices Market is valued at USD 590.65 Million in 2024 and is projected to reach a value of USD 1086 Million by 2035 at a ...

Combining an antiplatelet with oral anticoagulants in stroke patients with AF and cardiovascular disease slightly lowers ...

Explore how regenerative medicine is transforming healing and restoration in healthcare, and discover its potential benefits ...

ProMedica’s latest DAISY and ROSE award winners were praised by patients for their kindness, attentiveness and lasting impact ...

Classical hematologist Srila Gopal, MD, tackles the unique complexities of treating and researching sickle cell disease and ...

Single dose of avigbagene parvec (FLT201) demonstrates sustained clinical benefit and favorable safety up to two years after withdrawal of prior ...

The U.S. National Institutes of Health on Thursday launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with ...

Copeland is set to retire this month. As for what comes next, she says, “the opportunities feel endless.” ...

FoLix, the FDA-cleared laser treatment for hair loss, provides a surgery-free option and uses existing follicles on men and ...